Zurück
..... könnte heute richtig schön nach oben laufen
www.tradingview.com/symbols/OTC-RVVTF/
www.tradingview.com/symbols/OTC-RVVTF/
Revive Therapeutics Ltd. (RVV.CN)
Beiträge: 179
Zugriffe: 43.580 / Heute: 3
Zugriffe: 43.580 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +82,31%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +64,89%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +40,67%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +38,52%
Great post on Reddit. Peeps are starting to talk about it and the shorters would be toast.
www.reddit.com/r/RVVTF/comments/lhra14/...bucillamines_phase/
www.reddit.com/r/RVVTF/comments/lhra14/...bucillamines_phase/
RVVTF...387...Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury (“TBI”) in a rodent model of TBI. The study was conducted at the National Health Research Institutes (“NHRI”), which was part of the psilocybin program acquired from PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF)...
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury (“TBI”) in a rodent model of TBI. The study was conducted at the National Health Research Institutes (“NHRI”), which was part of the psilocybin program acquired from PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF)...
|
Neueste Beiträge aus dem Revive Therapeutics Ltd. Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 30 | Noch jemand investierst? | RandomGuy1 | bebe2 | 21.04.22 16:30 | ||
| 178 | Revive Therapeutics Ltd. (RVV.CN) | Chalifmann3 | axolot | 25.04.21 00:01 |
